Evidence map›Paper›PMID 26642332›Full record

Trial reportBone marrow transplantation2016

Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients?

M C Oliveira, M Labopin, J Henes, J Moore, N Del Papa, A Cras, I Sakellari, R Schroers, H U Scherer, A Cuneo and 8 more

Erratum issuedAbstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Guideline
  2. Guideline
  3. Guideline
  4. Trial
  5. Manufacture of Autologous CD34Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017
    Trial
  6. Trial
  7. Stem cell therapy in systemic sclerosis.Clinical rheumatology · 2025
    Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

M C OliveiraDivision of Clinical Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
M LabopinEBMT, Hôpital Saint Antoine, Paris, France.
J HenesMedizinische Universitätsklinik Abt. II, Tübingen, Germany.
J MooreDepartment of Haematology, St Vincent's Hospital, Sydney, New South Wales, Australia.
N Del PapaScleroderma Clinic, U.O.C. Day Hospital Rheumatology, Osp. G. Pini, Milan, Italy.
A CrasAssistance Publique-Hôpitaux de Paris, Saint-Louis Hospital, Cell Therapy Unit, Cord Blood Bank and CIC-BT501, Paris, France.
I SakellariBone Marrow Transplantation Unit, George Papanicolaou General Hospital, Thessaloniki, Greece.
R SchroersRuhr-Universität Bochum, Medizinische Klinik Knappschaftskrankenhaus, Bochum, Germany.
H U SchererDepartment of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands.
A CuneoUniversity of Ferrara-St Anna Hospital, Ferrara, Italy.
S Kyrcz-KrzemienDepartment of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Katowice, Poland.
T DaikelerDepartment of Rheumatology, University Hospital Basel, Basel, Switzerland.
T AlexanderDepartment of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany.
J FinkeDepartment of Medicine-Hematology and Oncology, University of Freiburg, Freiburg, Germany.
M BadoglioEBMT Paris Office, Hôpital Saint Antoine, Paris, France.
B SimõesDivision of Hematology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
J A SnowdenDepartment of Hematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
D FargeParis 7 University, INSERM U1160, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This EBMT Autoimmune Disease Working Party study aimed to evaluate the influence of CD34+ positive graft selection (CD34+) on the outcome of systemic sclerosis (SSc) patients after autologous hematopoietic stem cell transplantation (AHSCT). Clinical and laboratory data from 138 SSc patients at diagnosis, before and after AHSCT were retrospectively analyzed. CD34+ selection was performed in 47.1% (n=65) patients. By multivariate analysis adjusting for all factors differing between the two groups (without or with CD34+), there was no statistically significant difference in terms of overall survival (hazard ratio (HR): 0.98, 95% confidence interval (CI) 0.40-2.39, P=0.96), PFS (HR: 1.55, 95% CI 0.83-2.88, P=0.17) and incidence of relapse or progression (HR: 1.70, 95% CI 0.85-3.38, P=0.13). We demonstrate that CD34+ does not add benefit to the outcome of SSc patient treated with AHSCT. These findings should be further confirmed by prospective randomized trials.

Indexed as

Antigens, CD34AdolescentAdultAutograftsDisease-Free SurvivalFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedScleroderma, SystemicSurvival RateAntigens, CD34

Identifiers

PMID26642332

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.